systems options include implantable sacral nerve modulation (SNM) and percutaneous tibial nerve stimulation (PTNS), and only scarce data exist on implantable tibial nerve stimulation systems and none with long-term results. We hereby present 3-year follow-up results on the treatment of patients suffering from refractory OAB with the RENOVA iStimä System; an implantable tibial neurostimulation device.
INTRODUCTION AND OBJECTIVES: Overactive bladder (OAB) affects nearly half of women. Per AUA/SUFU treatment guidelines, patients should be offered first-line behavioral therapies, secondline medical treatment, and then third-line procedure-based treatment (botox injections or neuromodulation) if needed. Numerous studies have shown that most patients diagnosed with OAB are not prescribed medications and those who are discontinue medications within one year due to side effects, lack of efficacy, and/or cost. However, it remains unknown how frequently female patients in the U.S. progress from second-to third-line treatment in a real-world setting. The purpose of this study was to determine the proportion of women who undergo third-line treatment within two years of initiating medications.
METHODS: A retrospective cohort study of adult women diagnosed with non-neurogenic OAB and prescribed a second-line medical treatment was conducted using the Truven MarketScan, a nationally representative administrative claims database. All women aged 63 or less who had their first OAB medication prescription claim between January 1, 2013, and December 31, 2014, were included. Women were excluded if they did not have continuous enrollment for at least one year prior to and two years following their first prescription claim. The primary outcome was the proportion of women at two years following the first prescription claim who 1) never refilled their prescription, 2) discontinued their prescription, 3) had filled a prescription within the previous 90 days, and 4) received a third-line treatment.
RESULTS: Of the 17,429 women diagnosed with OAB and prescribed second-line medical treatment, nearly one-third (n[5,331, 30%) did not refill their prescription or receive third-line treatment within two years. A total of 6,295 (36%) women refilled their prescription at least once but discontinued their prescription by two years, and 4,265 (24%) had OAB medication claims at two years. Only 1,538 (9%) progressed from second-to third-line treatment, 383 (25%) of whom also had OAB medication claims at two years.
CONCLUSIONS: Two years after initiation of medications for OAB, two-thirds of women were neither on second-line medical treatment nor had undergone a third-line treatment. Less than 10% of women progressed from second-to third-line treatment. While it is not possible to assess symptom severity, response to treatment, or whether third-line treatments were offered in this claims database, when combined with findings from previous studies, these results highlight a potential gap in the treatment of women with OAB. We sought to quantify and determine how often new OAB patients follow up and utilize third line therapy before and after the implementation of the CCP.
METHODS: Our institution approved OAB database was queried for only new OAB patient visits. These patients were followed longitudinally over 12 months to determine rates of follow-up and utilization of third line therapies. New patients were divided into three distinct time periods: pre-CCP 2014-2015, post-CCP 2016, and post-CCP January 2017-June 2017. Outcomes were compared amongst groups. Our analysis encompassed 9 subspecialty trained urologists, including 1 FPRMS certified urologist.
RESULTS: A total of 1,114 new OAB patients were identified. There were 507, 430, and 176 patients in the pre-CCP, 2016 CCP, and 2017 CCP groups, respectively. After CCP implementation, follow-up rates significantly increased at 3, 6, and 12 months (Table 1) . Mean follow-up visits at 6 months and at 12 months increased significantly from pre-CCP to 2 years post-CCP (0.88-1.6, p<0.01 and 1.21-2.06, p<0.01, respectively). Additionally, the third line therapy utilization at 6 months increased from 4.7% pre-CCP to 10% two years post-CCP (p[0.02). In particular, percutaneous tibial nerve stimulation numbers significantly from 0.8% to 5.7% (p<0.01) at 6 months and 2.2% to 6.3% (p[0.03) at 12 months. The median days to third line therapy decreased from 199 to 85 (p<0.01). Specifically, the FPMRS provider had an increase in third line therapy utilization at 6 months from 8.1% pre-CCP to 16.4% two years post-CCP (p[0.054) and 12 month of 11.5% pre-CCP to 20.2% two years post-CCP (p[0.08). Within 1 year, patients also went on to a second third line therapy more frequently (0% vs. 3.1% and 1.9%, p[0.02).
CONCLUSIONS: This study demonstrates that after CCP implementation, new patients more reliably follow-up and follow-up quicker. Additionally, refractory patients progress quicker to third line therapies. Despite these findings, 35% of new OAB patients fail to follow-up within one year and utilization of third line therapies remains low.
INTRODUCTION AND OBJECTIVES:
The prevalence of bothersome overactive bladder (OAB) symptoms in men does not differ notably from that in women, but men are much less likely to receive treatment with OAB medications. Men's rates of continuation of OAB medications and progression to third-line OAB treatments (botulinum toxin or neuromodulation) remain unknown. This study investigated use of third-line OAB treatment in a real-word setting using a nationally-representative claims database.
METHODS: A retrospective cohort study of adult men diagnosed with non-neurogenic OAB between January 1, 2013 and September 30, 2014 was conducted using the Truven MarketScan Commercial Claims and Encounters Database. Men included in analyses had at least two claims on separate encounter dates with an OAB ICD-9 diagnosis code and were age 63 years or younger at their first claim. Men were excluded if they lacked continuous health insurance plan enrollment for at least one year before and two years following OAB diagnosis.
RESULTS: A total of 26,100 men were included; 3,492 (13.4%) were prescribed second-line OAB therapy (medications) within two years of OAB diagnosis. The median time from diagnosis to an OAB medication prescription was 44 days. Of the men prescribed OAB medications, 29% (1,004) maintained their prescription two years later. Within two years of their first OAB medication prescription, 50 men (1.4%) had undergone third-line OAB treatment, with a median time from diagnosis to third-line therapy of 281 days.
CONCLUSIONS: OAB may be undertreated in men, according to low rates of medication prescriptions for second-line therapy. Similar to women, this undertreatment is likely compounded by the frequent and rapid discontinuation of such medications, as well as low rates of progression from second-line to third-line therapy with either botulinum toxin or neuromodulation. Further studies on the diagnostic and treatment patterns of men with OAB are warranted to identify the factors underlying this undertreatment.
